May 2008
BioWorld Today;5/20/2008, Vol. 19 Issue 98, p4
This section offers news briefs on the pharmaceutical industry in 2008. Bayer HealthCare AG and Nektar Therapeutics Inc of San Carlos, California have developed a drug-device combination called Amikacin Inhale which can treat pneumonia. Epeius Biotechnologies Corp. reported positive study results for its Rexin-C, a medication for pancreatic cancer. NovaBay Pharmaceuticals Inc. has developed the drug Aganocide for the prevention and treatment of infectious diseases.


Related Articles

  • Nektar Keeps Promotion Rights In $175M Deal On Amikacin Drug. Shrine, Jim // BioWorld Today;8/7/2007, Vol. 18 Issue 152, p1 

    The article reports on the co-development and commercial collaboration between biotechnology companies Nektar Therapeutics Inc. and Bayer HealthCare AG for the Phase II inhaled amikacin product for pneumonia. Nektar Therapeutics Inc. is getting $50 million up front and will be retaining...

  • Nektar Therapeutics: Collaborating in Compliance. Summerfield, Brian // Chief Learning Officer;Oct2004, Vol. 3 Issue 10, p46 

    This article reports that Nektar Therapeutics, based in San Carlos, California, provides drug-delivery technologies to enable the development of a wide variety of high-value therapeutics. The company's drug-delivery capabilities are designed to help its biotechnology and pharmaceutical partners...

  • Halving Treatment Time. Breitstein, Jonna; N. T. M. // Pharmaceutical Executive;Nov2005, Vol. 25 Issue 11, p24 

    Reports on the collaboration between Bayer HealthCare AG and the Global Alliance for TB Drug Development. Significance of the collaboration for the improvement in the treatment of tuberculosis; Terms under the deal; Importance of the partnership to the pharmaceutical industry.

  • Special Delivery. Sellers, L.J. // Pharmaceutical Executive;Apr2004, Vol. 24 Issue 4, p66 

    Profiles Nektar Therapeutics, a pharmaceutical company which made two acquisitions in 2001, brokered 11 collaborative partnerships in 2002, and generated $106 million in sales in 2003. Chief executive officer Ajit Gill and chief scientific officer John Patton; Inhaled insulin product; PEG...

  • Compugen Rockets on $540M Bayer Immunotherapy Alliance. Boggs, Jennifer // BioWorld International;8/7/2013, Vol. 18 Issue 32, p1 

    The article reports on the 44.5 percent increase in the share price of Compugen Ltd., a drug discovery company, following news of a possible 540-million-dollar deal with pharmaceutical company Bayer Healthcare to develop cancer immunotherapy drugs. Compugen began operating in the 1990s as a...

  • 13 BAYER HEALTHCARE.  // Contract Pharma;Jul/Aug2011, Vol. 13 Issue 6, p94 

    The article reports on the performance of Leverkusen, Germany-based Bayer Healthcare AG in 2010 and its prospects for growth in 2011.

  • Deals roundup.  // Medical Device Daily;8/7/2007, Vol. 11 Issue 149, p3 

    The article reports on the partnership established between Tarrytown, New York-based Bayer HealthCare and San Carlos, California-based Nektar Therapeutics. The companies have agreed to develop and commercialize NKTR-061 (inhaled amikacin). The therapy would employ Nektar's pulmonary technology...

  • I&I News Round-Up.  // PharmaWatch: Monthly Review;Oct2009, Vol. 8 Issue 10, p15 

    The article offers news briefs related to pharmaceutical industries. Ranbaxy Laboratories Ltd. has been allowed by the Food and Drug Administration (FDA) to manufacture and market glycopyrrolate tablets USP 1mg and 2mg. An agreement to acquire Desonate and Neobenz micro from SkinMedica has been...

  • Chemical Efficiency Fragments. May, Mike // Drug Discovery & Development;Aug2007, Vol. 10 Issue 8, p12 

    The article offers world news briefs related to fragmentation in pharmaceutical firms. Evotec AG announces the development of its Innovation Center for Fragmented-Based Drug Discovery with EVOlution screening platform. A partnership is made between Bayer Healthcare AG and Prosteros Biostructures...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics